Replies to post #102734 on Biotech Values

[BTH]

I also find your blanket dismissal of ligand inhbitors amusing

Get a clue.

This entire conversation is related to Curis' GDC-0449 and it's action on the pathway. Not a "blanket" on ligand inhibitors.

So, you think Curis' CEO and Roche don't differentiate between mutation-driven and ligand-driven? LOL, maybe you should read the data from both parties, presentations, and the SEC filings, etc.